Recurrence and influencing factors of hepatitis B surface antigen seroclearance induced by peginterferon alpha-based regimens

Table 2 Univariate logistic regression analysis of the predictors of hepatitis B surface antigen recurrence

Characteristics	OR	95%CI	P value
Age (years)	0.962	(0.916-1.012)	0.133
Gender	1.692	(0.588-4.870)	0.329
Family history of HBV infection	0.655	(0.227-1.890)	0.434
Characteristics at the initiation of peg-IFN-α
HBsAg level, IU/mL	1.000	(1.000-1.000)	0.398
HBsAb negative	0.933	(0.107-8.130)	0.950
HBV DNA positive	0.514	(0.176-1.506)	0.225
HBeAg positive	1.448	(0.302-6.934)	0.643
Peg-IFN-α-2a	1.624	(0.558-4.730)	0.374
Peg-IFN-α monotherapy	0.588	(0.224-1.546)	0.282
Treatment time of peg-IFN-α (weeks)	1.014	(0.992-1.035)	0.217
Total duration of peg-IFN-α (weeks)	0.999	(0.975-1.024)	0.9570
Consolidation time < 12 weeks	25.636	(7.039-93.356)	< 0.001
Characteristics at the cessation of peg-IFN-α
Without HBsAg seroconversion	5.252	(1.684-16.376)	0.004
HBsAb, mIU/mL	0.952	(0.914-0.992)	0.018
HBsAb < 35.3 mIU/mL	9.705	(2.098-44.883)	0.004
HBsAb disappeared during the follow-up	14.500	(1.513-138.972)	0.020
ALT level at baseline, IU/L	1.011	(1.001-1.021)	0.127
FibroScan values at baseline (kPa)	1.314	(0.791-2.183)	0.292

HBV: Hepatitis B virus; Peg-IFN-α: Peginterferon alpha; HBsAg: Hepatitis B surface antigen; HBsAb: Hepatitis B surface antibody; ALT: Alanine aminotransferase; OR: Odds ratio.